Synthesis and pharmacology of the enantiomers of UH301: Opposing interactions with 5-HT1A receptors

Chirality

Volumn 8, Issue 8, 1996, Pages 531-544

  Hillver, Sven Erik ^a   Björk, Lena ^a   Höök, Berit Backlund ^a   Cortizo, Lourdes ^a   Nordvall, Gunnar ^b   Johansson, Anette M ^a   Ertan, Anne ^c   Csöregh, Ingeborg ^c   Johansson, Lars ^b   Lewander, Tommy ^d   Hacksell, Uli ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Astra Arcus AB   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

5 HT1A receptor antagonists; Enantiomers; Rat biochemistry; UH301

Indexed keywords

2 DIPROPYLAMINO 5 FLUORO 8 HYDROXYTETRALIN; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHIRALITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; NONHUMAN; PRIORITY JOURNAL; RAT; X RAY CRYSTALLOGRAPHY;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; BEHAVIOR, ANIMAL; BODY TEMPERATURE; CHEMISTRY, PHYSICAL; CRYSTALLOGRAPHY, X-RAY; DOPAMINE; MALE; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN; SEROTONIN ANTAGONISTS; STEREOISOMERISM;

EID: 3242855090     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-636X(1996)8:8<531::AID-CHIR1>3.0.CO;2-C     Document Type: Article

References (70)

1. For a recent overview of serotonin (5-HT) receptors see: 1996 Receptor & ion channel nomenclature supplement ISNN 1357 485X. Trends Pharmacol. Sci. 1996.
2. 1A serotonin ligands. J. Med. Chem. 31:1968-1971, 1988.
3. 1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin. Eur. J. Pharmacol. 154:339-341, 1988.
4. 1A antagonist. Drug Dev. Res. 16:335-343, 1989.
5. 1A serotonin binding sites? J. Med. Chem. 32:1921-1926, 1989.
6. 1A receptor antagonists: Utility as research tools and therapeutic agents. Trends Pharmacol. Sci. 14:441-448, 1993.
7. 1A receptors. J. Med. Chem. 36:1509-1510, 1993.
8. 1A receptors. Eur. J. Pharmacol. 237:283-291, 1993.
9. 1A receptor ligands (+)-WAY100135 and SDZ16-525. Eur. J. Pharmacol. 249:25-35, 1993.
10. 1A receptors in vivo. Eur. J. Pharmacol. 240:307-310, 1993.
11. e) Hartley, J., Fletcher, A. The effects of WAY-100135 and 8-hydroxy-2-(di-n-propylamino)tetralin on feeding in the rat. Eur. J. Pharmacol. 252:329-332, 1994.
12. 1A receptor antagonist, in the murine elevated plusmaze test. Eur. J. Pharmacol. 261:321-325, 1994.
13. 1A receptor antagonist. Br. J. Pharmacol. 112:p91, 1994.
14. 1A receptor antagonist WAY100635. Eur. J. Pharmacol. 264:95-97, 1994.
15. 1A receptors with positron emission tomography. Life Sci. 55:403-407, 1994.
16. 1A receptor antagonist. Brain Res. 673:217-225, 1995.
17. 3H]WAY-100635, a novel 5-hydroxytryptamine1A receptor antagonist, to rat brain. J. Neurochem. 64:2716-2726, 1995.
18. 1A receptors in rat brain membranes. Eur. J. Pharmacol. 288:173-186, 1995.
19. 1A-receptor antagonist. J. Med. Chem. 33:1541-1544, 1990.
20. a) Björk, L., Lindgren, S., Hacksell, U., Lewander, T. (S)-UH-301 antagonizes (R)-8-OH DPAT-induced cardiovascular effects in the rat. Eur. J. Pharmacol. 199:367-370, 1991.
21. b) Björk, L., Cornfield, L.J., Nelson, D.L., Hillver, S.-E., Anden, N.-E., Lewander, T., Hacksell, U. Pharmacology of the novel 5-HT1A-receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin, (S)-UH-301: Inhibition of (R)-8-OH DPAT-induced effects. J. Pharm. Exp. Ther. 258:58-65, 1991.
22. 1A receptor antagonist (S)-UH-301 antagonizes 8-OH-DPAT-induced effects on male as well as female rat copulatory behaviour. Eur. J. Pharmacol. 202:81-87, 1991.
23. d) Björk, L., Fredriksson, A., Hacksell, U., Lewander, T. Effects of (R)-8-OH DPAT and the enantiomers of UH-301 on motor activities in the rat. Antagonism of (R)-8-OH DPAT-induced effects. Eur. Neuropsychopharmacol. 2:141-147, 1992.
24. 1A receptor antagonist (S)-UH-301 prevents (R)-8-OH-DPAT-induced decrease in interstitial concentrations of serotonin in the rat hippocampus. Eur. J. Pharmacol. 216:373-378, 1992.
25. 1A receptor Antagonist (S)-UH-301 in Rodents and monkeys. Brain Res. Bull. 29:901-904, 1992.
26. 1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedeberg's Arch. Pharmacol. 347:353-362, 1993.
27. 1A receptor antagonist (S)-UH-301 blocks the (R)-8-OH-DPAT-induced inhibition of serotonergic dorsal raphe cell firing in the rat. J. Neural Transm. Gen. Sect. 96:179-186, 1994.
28. 1A receptor antagonist, enhances plasma corticosterone levels in the rat. Life Sci. 55:PL99-103, 1994.
29. 1A receptor. Eur. J. Pharmacol. 272:177-183, 1995.
30. a) Arvidsson, L.-E., Hacksell, U., Nilsson, J.L.G., Hjorth, S., Carlsson, A,. Sanchez, D., Lindberg, P., Wikström, H. 8-Hydroxy-2-di-n-propylaminotetralin, a new centrally acting 5-HT-receptor agonist J. Med. Chem. 24:921-923, 1981.
31. b) Hjorth, S., Carlsson, A., Lindberg, P., Sanchez, D., Wikstrom, H., Arvidsson, L.-E., Hacksell, U., Nilsson, J.L.G. 8-Hydroxy-2-(di-n-propylamino)tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT-receptor stimulating activity. J. Neural Transm. 55:169-188, 1982.
32. c) Arvidsson, L.-E., Hacksell, U., Johansson, A.M., Nilsson, J.L.G., Lindberg, P., Sanchez, D., Wikström, H., Svensson, K., Hjorth, S., Carlsson, A 8-Hydroxy-2-(alkylamino)-tetralins and related compounds as central 5-hydroxytryptamine receptor agonists. J. Med. Chem. 27:45-51, 1984.
33. d) Cornfield. L.J., Lambert, G., Arvidsson, L-E., Mellin, C., Vallgårda, J., Hacksell, U., Nelson, D.L. Intrinsic activity of enantiomers of 8-hydroxy-2-(di-n-propylamino)tetralin and its analogues at 5-hydroxytryptamine1A receptors that are negatively coupled to adenylate cyclase. Mol. Pharmacol. 39:780-787, 1991.
34. e) Arborelius, L., Nomikos, G.G., Hacksell, U., Svensson, T.H. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta. Physiol. Scand. 148:465-466, 1993.
35. a) Artigas, F. 5-HT and antidepressants: New views from microdialysis studies. Trends Pharmacol. Sci. 14:262, 1993.
36. b) Deakin, J.F.W., Graeff, F.G., Guimaraes, F.S. Clinical implication of microdialysis findings. Trends Pharmacol. Sci. 14:263, 1993.
37. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J. Neurochem. 60:776-779, 1993.
38. d) Blier, P., de Montigny, C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15:220-226, 1994.
39. 1A autoreceptors in the action of selective serotonin reuptake inhibitors. Eur. J. Pharmacol. 260:251-255, 1994.
40. 1A receptor antagonists increase the activity of serotoninergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:157-165, 1995.
41. a) Roe, A. Preparation of aromatic fluorine compounds from diazonium fluoborates. Org. Reaction 5:193-228, 1949.
42. b) Houben-Weyl, Methoden der organischen Chemie, George Thieme Verlag, Stuttgart, Vol. 5/3, 1962: 213-246.
43. Filler, R. Reactions of organic compounds with xenon fluorides. Israel J. Chem. 17:71-90, 1978.
44. Thomas, C.A. Anhydrous Aluminum Chloride. ACS Monograph Series No. 87, New York: Reinhold Publishing Corporation, 1941.
45. Taylor, E.C., Chiang, C.-S., McKillop, A. Thallium in organic synthesis. 47. Regioselective ring expansion of cyclic aralkyl ketones via Wittig-derived olefins with tallium(III) nitrate (TTN). Tetrahedron Lett. 1827-1830, 1977.
46. Backlund Höök, B., Johansson, A.M., Hjorth, S., Sundell, S., Hacksell, U. Synthesis of (+)-(R)- and (-)-(S)-5-Hydroxy-2-methyl-2-dipropylaminotetralin: Effects on rat hippocampal output of 5-HT, 5-HIAA, and DOPAC as determined by in vivo microdialysis. Chirality 5:112-119, 1993.
47. Karlén, A., Helander, A., Johansson, A.M., Kenne, L., Sundell, S., Hacksell, U. Conformational analysis of 2-aminotetralins: Molecular mechanics calculations, X-ray crystallography and nuclear magnetic resonance spectroscopy. J. Chem. Res. (S), 448-449, (M), 3028-3036, 1993.
48. Wavefunction Inc., 18401 Von Karman Ave., Suite 370, Irvine, CA 92715.
49. Arvidsson, L.-E., Karlén, Anders, Norinder, U., Kenne, L., Sundell, S., Hacksell, U. Structural factors of importance for 5-hydroxytryptaminergic activity. Conformational preferences and electrostatic potentials of 8-hydroxy-2-(di-n-propytamino)tetralin (8-OH-DPAT) and some related agents. J. Med. Chem. 31:212-221, 1988.
50. 1A Receptors. J. Med. Chem. 36:4221-4229, 1993.
51. Rényi, L., Archer, T., Minor B.G., Tandberg, B., Fredriksson, A., Ross, S.B. The inhibition of the cage-leaving response - a model for studies of the serotoninergic neurotransmission in the rat. J. Neural Transm. 65:193-210, 1986.
52. 2 receptors in different components of the 5-HT syndrome in the rat. Neuroscience 22:225P, 1987.
53. 2 receptors. J. Neural Transm. 62:231-248, 1985.
54. 1A receptor interactions J. Med. Chem. 38:647-658, 1995.
55. a value for phenol and 4-fluorophenol is 10.00 and 9.81, respectively.
56. Karlsson, A., Pettersson, C., Sundell, S., Arvidsson, L.-E., Hacksell, U. Improved preparation, chromatographic separation and X-ray crystallographic determination of the absolute configuration of the enantiomers of 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT). Acta. Chem. Scand. 842:231-236, 1988.
57. a) Björk, L., Mellin, C., Hacksell, U., Andén, N.-E. Effects of the C3-methylated derivatives of 8-hydroxy-2-(di-n-propylamino)tetratin (8-OH-DPAT) on central 5-hydroxytryptamine receptors. Eur. J. Pharmacol. 143:55-63, 1987.
58. b) Mellin, C., Björk, L., Karlén, A., Johansson, A.M., Sundell, S., Kenne, L., Nelson, D.L., Andén, N.-E., Hacksell, U. Central dopaminergic and 5-hydroxytryplaminergic effects of C3-methylated derivatives of 8-hydroxy-2-(di-n-propylamino)tetralin. J. Med. Chem. 31:1130-1140, 1988.
59. Buck, J.S., Cutler, R.A., Nachod, F.C., Powles, R.G., Rakoczy, R., Slauson, T.J., Tullar, B.F. Some chlorinated 4-indanols: Preparation and proof of structure. J. Am. Chem. Soc. 79:3559-3561, 1957.
60. Arvidsson, L.-E., Johansson, A.M., Hacksell, U., Nilsson, J.L.G., Svensson, K., Hjorth, S., Magnusson, T., Carlsson, A., Andersson, B., Wikström, H. (+)-cis-8-Hydroxy-1-methyl-2-(di-n-propylamino)tetralin: A potent and highly stereoselective 5-hydroxytryptamine receptor agonist. J. Med. Chem. 30:2105-2109, 1987.
61. Sheldrick, G.M., Phase annealing in SHELX-90: Direct methods for larger structures. Acta. Crystallogr. A46:467-473, 1990.
62. a) Sheldrick, G.M., SHELX76: Program for Crystal Structure Determination, University of Cambridge, England, 1976.
63. b) Sheldrick, G.M., SHELX 400 ATOM VERSION; updated by D. Rabinovich and K Reich; Department of Structural Chemistry, Weizmann Institute of Science, Rehovot, Israel; and subsequently modified by G.M. Sheldrick, University of Göttingen, Germany, 1979.
64. Hamilton, W.C., Significance test on the crystallographic R factor. Acta. Crystallogr. 18:502-510, 1965.
65. Rogers, D., On the application of Hamilton's ratio test to the assignment of absolute configuration and an alternative test Acta. Crystallogr. A37:734-741, 1981.
66. Nardelli, M. PARST: A system of FORTRAN routines for calculating molecular structure parameters from results of crystal structure analyses. Comput. Chem. 7:95-98, 1983.
67. Motherwell, S., Clegg, B. PLUTO: Program for Plotting Molecular and Crystal Structures, University of Cambridge, England, 1978.
68. Carlsson, A., Davis, J.N., Kehr, W., Undqvist, M., Atack, C.V. Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase. Naunyn-Schmiedeberg's Arch. Pharmacol. 275:153-168, 1972.
69. International Tables for X-Ray Crystallography, Vol. IV. Birmingham, England: The Kynoch Press, 1974.
70. Cromer, D.T., Liberman, D. Relativistic calculation of anomalous scattering factors for X-rays. J. Chem. Phys. 53:1891-1899, 1970.